Parfieniuk-Kowerda A - Search Results

1

Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals.

Flisiak R, Zarębska-Michaluk D, Berak H, Dybowska D, Sitko M, Parfieniuk-Kowerda A, Janocha-Litwin J, Janczewska E, Piekarska A, Lorenc B, Mazur W, Dobrowolska K, Tudrujek-Zdunek M, Klapaczyński J, Jaroszewicz J. Flisiak R, et al. Among authors: parfieniuk kowerda a. Clin Exp Hepatol. 2023 Sep;9(3):193-201. doi: 10.5114/ceh.2023.130935. Epub 2023 Sep 3. Clin Exp Hepatol. 2023. PMID: 37790681 Free PMC article.

2

Treatment of chronic hepatitis C in a patient with Fanconi anaemia.

Rogalska-Płońska M, Parfieniuk-Kowerda A, Lapiński TW, Flisiak R. Rogalska-Płońska M, et al. Adv Med Sci. 2011;56(2):366-8. doi: 10.2478/v10039-011-0011-5. Adv Med Sci. 2011. PMID: 21940271

3

Exacerbation of chronic hepatitis B during chemotherapy due to testicular seminoma.

Parfieniuk-Kowerda A, Rogalska-Plonska M, Lapinski WT, Flisiak R. Parfieniuk-Kowerda A, et al. Hepatogastroenterology. 2012 Jun;59(116):1258-9. doi: 10.5754/hge09108. Hepatogastroenterology. 2012. PMID: 22580677

4

[Occurrence of autoantibodies in patients with alcoholic liver disease].

Szulzyk T, Parfieniuk-Kowerda A, Luto M, Lapiński TW, Flisiak R. Szulzyk T, et al. Pol Merkur Lekarski. 2012 Sep;33(195):143-6. Pol Merkur Lekarski. 2012. PMID: 23157132 Polish.

5

Assessment of serum IGF-1 and adipokines related to metabolic dysfunction in HIV-infected adults.

Parfieniuk-Kowerda A, Czaban SL, Grzeszczuk A, Jaroszewicz J, Flisiak R. Parfieniuk-Kowerda A, et al. Cytokine. 2013 Oct;64(1):97-102. doi: 10.1016/j.cyto.2013.07.018. Epub 2013 Aug 12. Cytokine. 2013. PMID: 23941777

6

Serum cytochrome c and m30-neoepitope of cytokeratin-18 in chronic hepatitis C.

Parfieniuk-Kowerda A, Lapinski TW, Rogalska-Plonska M, Swiderska M, Panasiuk A, Jaroszewicz J, Flisiak R. Parfieniuk-Kowerda A, et al. Liver Int. 2014 Apr;34(4):544-50. doi: 10.1111/liv.12297. Epub 2013 Aug 28. Liver Int. 2014. PMID: 23981197

7

Emerging treatments for hepatitis C.

Flisiak R, Jaroszewicz J, Parfieniuk-Kowerda A. Flisiak R, et al. Expert Opin Emerg Drugs. 2013 Dec;18(4):461-75. doi: 10.1517/14728214.2013.847089. Epub 2013 Oct 8. Expert Opin Emerg Drugs. 2013. PMID: 24102413 Review.

8

HBV mutations associated with lamivudine therapy.

Lapiński TW, Parfieniuk-Kowerda A, Trzos A, Jaroszewicz J, Kowalczuk O, Nikliński J, Flisiak R. Lapiński TW, et al. Przegl Epidemiol. 2013;67(4):611-6, 705-8. Przegl Epidemiol. 2013. PMID: 24741905 Free article. English, Polish.

9

Influence of HCV and HIV on development of cryoglobulinemia.

Rogalska-Płońska M, Lapinski TW, Grzeszczuk A, Parfieniuk-Kowerda A, Flisiak R. Rogalska-Płońska M, et al. Viral Immunol. 2015 Apr;28(3):145-52. doi: 10.1089/vim.2014.0114. Epub 2015 Feb 27. Viral Immunol. 2015. PMID: 25723551

10

Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection.

Łucejko M, Parfieniuk-Kowerda A, Flisiak R. Łucejko M, et al. Expert Opin Pharmacother. 2016 Jun;17(8):1153-64. doi: 10.1080/14656566.2016.1176143. Epub 2016 Apr 26. Expert Opin Pharmacother. 2016. PMID: 27064432

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

37 results

Search Page